FLAMEL TECHNOLOGIES S.A. (NASDAQ:FLML) Files An 8-K Other Events
Item 8.01 Other Events.
release, a copy of which is furnished as Exhibit 99.1 to this
current report on Form 8-K and is incorporated herein by
reference.
|
99.1
|
Press release of Flamel Technologies S.A. dated as of
December 16, 2016. |
About FLAMEL TECHNOLOGIES S.A. (NASDAQ:FLML)
Flamel Technologies S.A. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms. The Company owns and develops drug delivery platforms, including Micropump, LiquiTime, Trigger Lock and Medusa. The Company has two direct operating subsidiaries: Flamel US Holdings, Inc. and Flamel Irish Holdings, Ltd. FLAMEL TECHNOLOGIES S.A. (NASDAQ:FLML) Recent Trading Information
FLAMEL TECHNOLOGIES S.A. (NASDAQ:FLML) closed its last trading session down -0.15 at 10.06 with 98,564 shares trading hands.
